DA
YMAB

Denali Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

Denali Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,400
Closed -$112K – 508
2023
Q4 		$112K Sell
16,400
-69,500
-81% -$402K 0.03% 267
2023
Q3 		$468K Hold
85,900
– – 0.16% 144
2023
Q2 		$583K Buy
85,900
+77,600
+935% +$582K 0.2% 128
2023
Q1 		$41.6K Buy
+8,300
New +$33.9K 0.02% 234

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Denali Advisors's YMAB Position: Q1 2024 in Review

Denali Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q1 2024, closing a stake of 16,400 shares — an estimated $112K sold.

Denali Advisors first reported a position in YMAB in Q1 2023 and held it in 4 quarters. The position peaked at $583K in Q2 2023. 96 funds tracked by Wall St. Rank hold YMAB as of Q1 2024.

  • Denali Advisors reported no remaining Y-mAbs Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Denali Advisors sold 16,400 Y-mAbs Therapeutics shares in Q1 2024, an estimated $112K.
  • Denali Advisors first reported a position in Y-mAbs Therapeutics in Q1 2023 and held it in 4 quarters.
  • Denali Advisors's Y-mAbs Therapeutics position peaked at $583K in Q2 2023.
  • 96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2024.

Based on Denali Advisors's 13F filing for Q1 2024, filed 19 Apr 2024.